Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NZC7: Variant p.Pro47Arg

WW domain-containing oxidoreductase
Gene: WWOX
Feedback?
Variant information Variant position: help 47 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Proline (P) to Arginine (R) at position 47 (P47R, p.Pro47Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (P) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In DEE28. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 47 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 414 The length of the canonical sequence.
Location on the sequence: help TKDGWVYYANHTEEKTQWEH P KTGKRKRVAGDLPYGWEQET The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         TKDGWVYYANHTEEKTQWEHPKTGKRKRVAGDLPYGWEQET

Mouse                         TKDGWVYYANHTEEKTQWEHPKTGKRKRVAGDLPYGWEQET

Chicken                       TKDGWVYYANHLEEKTQWEHPKSGKRKRVAGGLPYGWEQET

Zebrafish                     TKDGWVYYANHEEMKTQWEHPKTGKKKRCAGALPYGWEQET

Drosophila                    TDDGTVCYVNQQGKTSQWTHPRTGRSKRITGELPLGWEKYY
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 414 WW domain-containing oxidoreductase
Domain 16 – 49 WW 1
Modified residue 33 – 33 Phosphotyrosine
Alternative sequence 36 – 36 N -> K. In isoform 4.
Alternative sequence 37 – 414 Missing. In isoform 4.
Mutagenesis 28 – 28 K -> T. No effect on interaction with TP53. Abolishes interaction with MAPK8; when associated with V-29.
Mutagenesis 29 – 29 D -> V. No effect on interaction with TP53. Abolishes interaction with MAPK8; when associated with T-28.
Mutagenesis 33 – 33 Y -> F. Loss of phosphorylation.
Mutagenesis 33 – 33 Y -> R. Abolishes interaction with TP53, TP73, MAPK8 and ERBB4. Partial loss of interaction with TFAP2C. Loss of phosphorylation. Loss of the proapoptotic activity. Abolishes binding to VOPP1.
Mutagenesis 44 – 47 WEHP -> FEHA. Abolishes interaction with LITAF.
Mutagenesis 61 – 61 Y -> R. No effect on interaction with TP73.



Literature citations
WWOX-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation.
Mignot C.; Lambert L.; Pasquier L.; Bienvenu T.; Delahaye-Duriez A.; Keren B.; Lefranc J.; Saunier A.; Allou L.; Roth V.; Valduga M.; Moustaine A.; Auvin S.; Barrey C.; Chantot-Bastaraud S.; Lebrun N.; Moutard M.L.; Nougues M.C.; Vermersch A.I.; Heron B.; Pipiras E.; Heron D.; Olivier-Faivre L.; Gueant J.L.; Jonveaux P.; Philippe C.;
J. Med. Genet. 52:61-70(2015)
Cited for: INVOLVEMENT IN DEE28; VARIANT DEE28 ARG-47;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.